BACKGROUND/AIMS: The prognosis of hepatic metastasis from gastric carcinoma is dismal. A few patients are candidates for hepatic resection. The present study analyzed the oncologic outcomes of hepatic resection performed in metachronous hepatic metastasis from gastric cancer. METHODOLOGY: Between January 1986 and November 2007, 14 patients underwent hepatectomy for metachronous hepatic metastasis secondary to gastric adenocarcinoma. Clinicopathological data were reviewed retrospectively. RESULTS: The median interval between gastrectomy and hepatectomy was 12.9 months. The numbers of hepatic lesions were single in 9 patients, more than two in 5 patients. The overall survival rates following hepatectomy were 67.0% at 1 year, 38.3% at 3 year. The disease progression occurred in 10 patients in the remaining liver. CONCLUSION: Surgical resection could be a treatment option for the hepatic metastasis from gastric cancer. The comparison of efficacy between surgical resection and the other treatment modalities will be required.
BACKGROUND/AIMS: The prognosis of hepatic metastasis from gastric carcinoma is dismal. A few patients are candidates for hepatic resection. The present study analyzed the oncologic outcomes of hepatic resection performed in metachronous hepatic metastasis from gastric cancer. METHODOLOGY: Between January 1986 and November 2007, 14 patients underwent hepatectomy for metachronous hepatic metastasis secondary to gastric adenocarcinoma. Clinicopathological data were reviewed retrospectively. RESULTS: The median interval between gastrectomy and hepatectomy was 12.9 months. The numbers of hepatic lesions were single in 9 patients, more than two in 5 patients. The overall survival rates following hepatectomy were 67.0% at 1 year, 38.3% at 3 year. The disease progression occurred in 10 patients in the remaining liver. CONCLUSION: Surgical resection could be a treatment option for the hepatic metastasis from gastric cancer. The comparison of efficacy between surgical resection and the other treatment modalities will be required.
Authors: Leila Sisic; Moritz J Strowitzki; Susanne Blank; Henrik Nienhueser; Sara Dorr; Georg Martin Haag; Dirk Jäger; Katja Ott; Markus W Büchler; Alexis Ulrich; Thomas Schmidt Journal: Gastric Cancer Date: 2017-07-24 Impact factor: 7.370
Authors: Claus W Schildberg; R Croner; S Merkel; V Schellerer; V Müller; S Yedibela; W Hohenberger; G Peros; A Perrakis Journal: World J Surg Date: 2012-04 Impact factor: 3.352
Authors: Claus W Schildberg; Thomas Weidinger; Werner Hohenberger; Axel Wein; Melanie Langheinrich; Markus Neurath; Frank Boxberger Journal: World J Surg Date: 2014-02 Impact factor: 3.352